Nexus awarded US FDA for Isoproterenol Hydrochloride Injection ANDA for heart block.
M2 EQUITYBITES-August 4, 2017-Nexus awarded US FDA for Isoproterenol Hydrochloride Injection ANDA for heart block
(C)2017 M2 COMMUNICATIONS http://www.m2.com
Healthcare company Nexus Pharmaceuticals reported on Thursday the receipt of approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Isoproterenol Hydrochloride Injection for mild or transient episodes of heart block.
In conjunction, the Isoproterenol Hydrochloride Injection is available in a single dose vial containing 0.2 mg per 1ml or 1 mg/5 ml, Isuprel, according to the company.
The company said the Isoproterenol Hydrochloride Injection USP is the first-to-market generic for Isuprel (Isoproterenol Hydrochloride Injection)
Isoproterenol Hydrochloride Injection USP is indicated for mild or transient episodes of heart block, for serious episodes of heart block and Adams-Stokes attacks, use in cardiac arrest until electric shock or pacemaker therapy, bronchospasm occurring during anesthesia, as an adjunct to fluid and electrolyte replacement therapy as well as in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure and cardiogenic shock, concluded the company.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Aug 4, 2017|
|Previous Article:||FI First Home Bank Closes Acquisition of Colorado's Stockmens Bank.|
|Next Article:||Alibaba Group partners with Macau SAR Government for Macau's digital transformation.|